Last reviewed · How we verify
NCT06789159
A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)
Phase 1 trial testing VK-2019 in Diffuse Large B Cell Lymphoma Refractory in 30 participants. Currently enrolling.
1 October 2028
Quick facts
| Lead sponsor | Thomas Jefferson University |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 22 May 2025 |
| Primary completion | 1 October 2028 |
| Estimated completion | 1 October 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- VK-2019 — full drug profile →
Conditions studied
- Diffuse Large B Cell Lymphoma Refractory — all drugs for Diffuse Large B Cell Lymphoma Refractory →
- Diffuse Large B Cell Lymphoma Relapsed — all drugs for Diffuse Large B Cell Lymphoma Relapsed →
- Epstein-Barr Virus (EBV) Infection — all drugs for Epstein-Barr Virus (EBV) Infection →
Sponsor
Thomas Jefferson University
Who can join
18 and older, any sex, with Diffuse Large B Cell Lymphoma Refractory or Diffuse Large B Cell Lymphoma Relapsed. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase Ib in adult patients with relapsed or refractory EBV-positive DLBCL using daily oral dosing of VK-2019 in three dose escalation cohorts: 600 mg/day, 1200 mg/day, 1800 mg/day for 28 days (cycle), until progression or toxicity.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06789159
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of VK-2019
Trials testing the same drug.
- NCT04925544 — Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer · Phase 2 · active not recruiting
- NCT03682055 — Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) · Phase 1, PHASE2 · terminated
Other Thomas Jefferson University trials
Trials by the same sponsor.
- NCT07526480 — Improving Dementia Care in Primary Practice · NA · not yet recruiting
- NCT07414550 — Radiotherapy for Refractory Hidradenitis Suppurativa · NA · not yet recruiting
- NCT07402018 — Intra-aortic Balloon Counterpulsation (IABC) Compliance · recruiting
- NCT07217197 — Respiratory Monitoring System That Detects & Predicts OIRD · NA · enrolling by invitation
- NCT07145099 — The IMPACT Study: Personalized Physical Therapy for Better Recovery and a Stronger Core After Hernia Surgery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06789159 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Thomas Jefferson University
- Last refreshed: 20 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06789159.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing